ArticleOncology research2025
Transglutaminase 7 Silencing Inhibits Proliferation and Modulates Inflammatory and Apoptotic Markers in Testicular Germ Cell Tumors.
Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oxaliplatin-induced testicular toxicity is associated with transglutaminase-4 upregulation, hormonal dysregulation, and inflammatory responses.Journal of applied biomedicine · 2026Article
- Human Transglutaminases: Updated Insights into Activation Mechanisms, Allosteric Regulation and Disease.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Testicular germ cell tumors (TGCTs) represent the most common malignancy among young men aged 20-40 years. Transglutaminase 7 (TG7), encoded by Methods: TG7 protein expression was evaluated in clinical testicular tissue samples via immunohistochemistry (IHC) and immunofluorescence (IF). Functional analysis was conducted in the NT2/D1 human testicular cancer cell line using Dicer-substrate small interfering RNAs (DsiRNAs) targeting TG7. Gene knockdown efficiency was confirmed by reverse transcription quantitative PCR (qRT-PCR), and protein suppression was validated by immunofluorescence. Cell viability was assessed using the MTT assay. The expression of inflammation and apoptosis-related genes was quantified via qRT-PCR. Results: TG7 expression was significantly elevated in testicular germ cell tumor tissues, showing approximately a 4.5-fold increase compared to normal testis, with strong localization in tumor nests and stromal compartments. In NT2/D1 cells, TG7 silencing using 20 nM DsiRNA3 led to a dose-dependent reduction in cell viability, with up to 48% inhibition observed at 200 nM (MTT assay, **** Conclusion: Collectively, TG7 is significantly overexpressed in TGCT tissues and supports tumor cell viability
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.